hypoxic-ischemic brain damage
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: (1) The gestational age of the child is 37 to 40 weeks, and the birth weight is > 2500 g; (2) There is a clear history of abnormal obstetrics that can lead to fetal distress, and severe intrauterine distress (fetal heart rate <100 beats/min for more than 5 minutes; and/or grade III contamination of amniotic fluid), or in A history of obvious asphyxia during childbirth; (3) Severe asphyxia at birth, which refers to Apgar score = 3 points at 1 minute, and = 5 points at 5 minutes, and/or umbilical arterial blood gas pH at birth = 7.00; (4) Neurological symptoms appear shortly after birth and persist for more than 24 hours; (5) The child was born with bruising, paleness, respiratory and circulatory failure, etc.; (6) The children's family members signed the informed consent form after knowing it.
Exclusion criteria
Exclusion criteria: (1) Children with hereditary abnormal glucose and lipid metabolism; (2) Children with congenital heart and lung diseases; (3) Those who have a history of allergy to the drug in this study; (4) Patients with severe liver, kidney and heart dysfunction; (5) Children with congenital malformations, inborn errors of metabolism, congenital viral and bacterial infections; (6) Children with intracranial hemorrhage or other craniocerebral injury; (7) Children with severe heart failure, pulmonary hypertension or severe anemia; (8) Any medical or non-medical condition that the investigator considers inappropriate to participate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes of intestinal flora and metabolites;neuron-specific enolase, NSE;S-100B protein,SI00B;brain-derived neurotrophic factor,BDNF; | — |
Secondary
| Measure | Time frame |
|---|---|
| gestational age;birth weight;Birth head circumference;Production mode;Apgar score;Days in hospital;Discharge gestational age;Discharge weight;Days of antibiotic use;C-reactive protein;white blood cell;hemoglobin;platelet;Procalcitonin; | — |
Countries
China
Contacts
Department of Anesthesiology, Fujian Provincial Hospital